Cyclo Therapeutics On Track To Commence Enrollment & Dosing Of Phase 2 Study Of Trappsol Cyclo For Treatment Of Alzheimer’s Disease Before Year End
– Company on track to commence enrollment and dosing of Phase 2 study of Trappsol® Cyclo™ for the treatment of Alzheimer's disease before year end
– Ongoing advancement of global pivotal study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1)